Human papillomavirus-positive oropharyngeal squamous cell carcinoma, a cancer of the tonsils and base of tongue that has become the dominant form of head and neck cancer in many Western countries, generally carries a favorable prognosis compared with its HPV-negative counterpart. Even so, between 10 and 25 percent of patients experience progressive disease within three years of treatment, making reliable surveillance a central concern for clinicians. The standard follow-up regimen typically involves contrast-enhanced CT of the neck and chest or PET/CT scanning, interpreted using the Neck Imaging Reporting and Data System, known as NI-RADS, a structured risk classification designed to standardize how radiologists flag suspicious findings. Yet imaging after surgery is complicated by anatomical distortion, scar tissue, and inflammation, all of which can mimic or obscure tumor recurrence.

The UNC team, led by Makayla R. Matthews of the School of Medicine together with colleagues in otolaryngology, radiology, and radiation oncology, reviewed the records of patients treated with definitive surgical resection between 2020 and 2023. All patients underwent standard post-treatment imaging, and ctHPVDNA samples were also collected and independently assessed. The cohort was characteristic of the modern HPV-positive throat cancer epidemic: 81 percent of the patients were male, the median age was 58, and a majority had never smoked. Most tumors arose in the tonsil, followed by the base of tongue, and nearly all patients presented with lymph node involvement, ranging from N1 to N3 disease under the seventh edition of the American Joint Committee on Cancer staging system.

During follow-up, four of the sixteen patients, or 25 percent of the cohort, developed biopsy-proven recurrence, with half of those events occurring at locoregional sites and half at distant locations. The median time to detectable recurrence was 14 months, though the range was wide, spanning from 3 to 42 months after treatment. This recurrence burden aligns with the upper end of what has been reported for HPV-positive oropharyngeal cancer populations and underscores why surveillance strategies matter: catching a returning tumor early, while it is still small and localized, can open the door to potentially curative salvage therapy.

The performance gap between the two surveillance modalities was the study’s most consequential finding. When radiologists applied NI-RADS criteria to post-treatment imaging, they flagged four suspected locoregional recurrences. Only one of these proved to be a true positive on biopsy; the other three were false positives. That translates to a sensitivity of 50 percent, a specificity of 75 percent, a positive predictive value of just 25 percent, and a negative predictive value of 90 percent for imaging-based detection. In practical terms, imaging missed as many recurrences as it caught, and three-quarters of the positive imaging findings did not correspond to actual cancer.

The ctHPVDNA assay told a different story. The blood test correctly identified two locoregional recurrence events and two distant recurrence events, all four of which were confirmed by biopsy, and it produced no false positives. That yields 100 percent sensitivity, 100 percent specificity, 100 percent positive predictive value, and 100 percent negative predictive value within this small cohort. The assay works on a principle analogous to liquid biopsies developed for other cancers: tumors driven by HPV shed fragments of viral DNA that carry tumor-tissue-modified signatures into the circulation, where they can be quantified using digital PCR. Because the viral signal originates from malignant cells rather than normal tissue, a positive result carries strong biological specificity for active disease.

The technical logic of the test helps explain its precision. HPV-positive tumor cells release short fragments of viral DNA, modified by the tumor tissue, into the plasma. Digital PCR platforms such as the one behind NavDx amplify and count these target sequences, producing a quantitative measure of circulating tumor burden. Unlike imaging, which depends on anatomical changes large enough to be visually resolved, the molecular assay can in principle register subclinical disease before structural changes appear on scans. The study’s finding that ctHPVDNA detected distant recurrences as well as locoregional ones is particularly notable, since distant metastases in the lungs or elsewhere are often the hardest events for routine neck imaging to catch early.

The clinical implications extend beyond diagnostic statistics. False-positive imaging findings in this study triggered additional workup and, in some cases, raised the specter of unwarranted salvage operations, procedures that carry real morbidity, heighten patient anxiety, and add substantial financial toxicity. The authors argue that a surveillance strategy anchored in ctHPVDNA could reduce the need for repeat imaging and prevent unnecessary interventions, reserving invasive procedures for patients whose molecular signal confirms genuine disease. Conversely, the high negative predictive value suggests that a clear blood test could offer patients and clinicians greater confidence that no recurrence is present, potentially streamlining follow-up schedules that currently rely on serial scanning.

Important caveats temper these results. The study was a single-institution retrospective review with only sixteen patients and four recurrence events, a level of evidence the authors themselves classify as level 4. Perfect sensitivity and specificity in such a small sample will almost certainly narrow in larger, prospective validations, and the assay’s performance in patients treated primarily with radiation rather than surgery remains to be established in this dataset. Questions also persist about optimal testing frequency, the quantitative thresholds that best distinguish clinically meaningful disease from transient signal, and how ctHPVDNA results should be integrated with imaging rather than simply replacing it, since anatomical localization remains essential for planning any salvage treatment.

Nevertheless, the findings add to a growing body of evidence that molecular surveillance of HPV-associated cancers can outperform anatomical imaging, echoing the way prostate-specific antigen transformed monitoring of prostate cancer decades ago. For a cancer population that is young, often curatively treated, and destined to live for decades under surveillance, the prospect of a blood test that reliably rules recurrence in or out carries enormous weight, both medically and psychologically. Larger prospective studies will determine whether ctHPVDNA surveillance can move from promising retrospective data to standard practice, but this early signal from surgical patients suggests that the era of watching for returning throat cancer with blood rather than scanners may be drawing closer.

Subject of Research: Circulating tumor HPV DNA surveillance for recurrence detection in surgically treated HPV-positive oropharyngeal squamous cell carcinoma

Article Title: NavDx (ctHPVDNA) recurrence detection in surgically treated human papillomavirus-associated oropharyngeal squamous cell carcinoma

Article References: Matthews, M. R., Van Dorsten, A. L., Heetderks, K. A., Yarbrough, W. G., Oldan, J. D., Huang, B. Y., Shen, C., & Hackman, T. G. (2026). NavDx (ctHPVDNA) recurrence detection in surgically treated human papillomavirus-associated oropharyngeal squamous cell carcinoma. BMC Cancer. https://doi.org/10.1186/s12885-026-17011-0

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17011-0

Keywords: HPV-positive oropharyngeal cancer, circulating tumor HPV DNA, liquid biopsy, NavDx, cancer recurrence surveillance, NI-RADS imaging, head and neck cancer, digital PCR, salvage surgery, tumor tissue modified viral DNA, post-treatment monitoring, BMC Cancer

The core of Demircan’s critique rests on a principle familiar to every epidemiologist: treatment effect and treatment selection are two very different things. When patients are not randomized, the group that receives one therapy is often systematically different from the group that receives another, and any difference in outcomes may reflect those baseline differences rather than the therapy itself. In the study under scrutiny, patients who underwent microsurgical resection had greater baseline motor impairment than those allocated to stereotactic radiotherapy. That detail matters enormously, because a patient who enters treatment with a weakened arm or leg has far more room to demonstrate measurable improvement than a patient whose motor function is already intact. Improvement in the surgical cohort and stability in the radiotherapy cohort may therefore describe the same underlying quality of care, even though the numbers appear to favor one arm over the other.

This asymmetry in scoring is more than a statistical quirk. Functional outcome scales typically capture change from baseline, so a patient who regains the ability to walk after tumor decompression registers a dramatic gain, while a patient who never lost the ability to walk and remains unchanged after focused radiation registers only stability. Yet clinically, preserving intact neurological function is precisely the goal of treating a metastasis in eloquent motor cortex without opening the brain. Demircan points out that categorizing preserved near-intact function after stereotactic radiotherapy as mere stability understates what is, for those patients, a meaningful and desirable result. The apparent superiority of surgery may, in part, be an artifact of the yardstick rather than a genuine therapeutic advantage.

The second major concern involves what statisticians call informative crossover, and here the numbers are striking. Of the 41 patients initially allocated to stereotactic radiotherapy, 17 ultimately required salvage surgery, either because their tumors progressed or because they developed a new neurological deficit despite irradiation. That is a crossover rate of roughly 41 percent, and all of those patients were excluded from the comparative radiotherapy cohort. What remains in the analyzed group is, by construction, the subset of patients for whom radiotherapy succeeded. This is a form of survivorship bias built directly into the study design: the radiotherapy arm is pre-selected for good outcomes, while the failures are silently transferred out of view. Any comparison between the trimmed radiotherapy cohort and the surgical cohort will therefore flatter radiotherapy less than an intention-to-treat analysis would, or, depending on how the comparison is framed, obscure the clinically important fact that a substantial minority of radiotherapy patients fared poorly and needed rescue operations.

Demircan emphasizes that this 41 percent crossover does double duty. It simultaneously selects the analyzed radiotherapy cohort for patients in whom the treatment worked, and it identifies a subgroup with genuinely poor outcomes after initial radiotherapy, patients who progressed or deteriorated neurologically and required surgery anyway. For clinicians counseling a patient, that subgroup is not a footnote; it is central to the decision. A patient with a metastasis in the motor cortex wants to know not only the average outcome of each strategy but also the risk that the first choice will fail and leave them worse off. When more than four in ten patients initially assigned to radiotherapy end up needing surgery, the effective comparison is no longer surgery versus radiotherapy but surgery versus radiotherapy followed, in many cases, by surgery after all.

A third layer of complexity concerns what the surgical arm actually received. Postoperative radiotherapy was administered to 95 percent of surgically treated patients with available data. This means the study did not compare surgery alone with radiotherapy alone; it compared a multimodality package, microsurgical resection followed by adjuvant irradiation, against definitive stereotactic radiotherapy. The distinction is far from academic. Landmark randomized trials, including the phase 3 studies by Mahajan and colleagues and Brown and colleagues published in Lancet Oncology in 2017, established that postoperative stereotactic radiosurgery reduces local recurrence after resection but carries its own considerations regarding toxicity and cognitive outcomes. Attributing the combined strategy’s results to surgery alone would misrepresent the intervention patients actually underwent and could mislead centers that lack the full multidisciplinary apparatus the combined approach presumes.

Compounding all of this, the extent of resection was not reported. In neurosurgical oncology, the degree to which a tumor is removed is one of the strongest determinants of local control, particularly when adjuvant radiation is planned. A gross-total resection followed by cavity radiosurgery behaves very differently biologically from a subtotal decompression, both in terms of residual tumor cells and in the dose constraints that nearby motor pathways impose on the radiation plan. Without knowing how complete the resections were, readers cannot disentangle how much of the local control in the surgical arm came from the operation itself and how much from the postoperative irradiation that nearly all of those patients received. Demircan argues that this missing variable further complicates any interpretation of the study’s local control data and its functional outcomes.

None of this means the study is without value. Demircan is explicit that the findings do support microsurgical resection for appropriately selected patients, particularly those with large, symptomatic lesions that require rapid decompression. When a tumor is exerting mass effect on motor pathways and a patient is losing function hour by hour, focused radiation cannot act quickly enough, and surgical relief is the only option that restores room for the brain to recover. The critique is narrower and more precise: the data do not establish that surgery produces better functional outcomes than stereotactic radiotherapy once treatment selection is properly accounted for. Those are two very different claims, and conflating them could push clinical practice toward aggressive intervention in patients who would do just as well, with less risk, under a radiation-first strategy.

The path forward, according to the correspondence, lies in how future studies are designed and reported. Outcomes should be tracked from the initial treatment allocation all the way through salvage therapy, so that the true cost of each starting strategy, including its failure rate, is visible rather than hidden by cohort trimming. Analyses should incorporate the variables that actually drive decisions and outcomes in this population: lesion volume, baseline neurological status, involvement of the corticospinal tract as mapped by diffusion tensor imaging and navigated transcranial magnetic stimulation, the extent of resection achieved, the burden of systemic disease, and the urgency of decompression. Advanced imaging and tractography techniques, already being used to spare motor structures in adjuvant radiotherapy planning, offer a way to individualize these decisions with far greater anatomical precision than was possible a decade ago.

For patients and clinicians, the takeaway is a familiar lesson in modern oncology delivered in an unfamiliar setting. Observational comparisons, however carefully assembled, are hostage to the forces that determine who receives which treatment. In motor cortex metastases, those forces, performance status, motor function, tumor size, and disease burden, are precisely the factors that also shape functional outcomes, making confounding especially potent. The study by Kraus and colleagues adds real evidence that surgery can serve selected patients well, and the correspondence by Demircan sharpens that evidence into something clinically usable: a reminder that preserved function after radiation is a success worth counting, that crossover is a result worth reporting, and that the question is not simply which treatment works, but which treatment works for which patient, under which circumstances, measured from the moment the first decision is made.

Subject of Research: Interpreting functional outcomes and treatment selection bias in managing brain metastases of the primary motor cortex

Article Title: Treatment selection or treatment effect? Interpreting functional outcomes in motor cortex metastases

Article References: Demircan, V. (2026). Treatment selection or treatment effect? Interpreting functional outcomes in motor cortex metastases. Journal of Neuro-Oncology, 179(2), Article 72. https://doi.org/10.1007/s11060-026-05787-x

Image Credits: AI Generated

DOI: 10.1007/s11060-026-05787-x

Keywords: brain metastases, motor cortex, microsurgical resection, stereotactic radiotherapy, treatment selection bias, functional outcomes, crossover, postoperative radiotherapy, extent of resection, corticospinal tract, neuro-oncology, salvage surgery

The most mature evidence concerns what happens after surgery. The phase III CheckMate 577 trial established adjuvant nivolumab as the global standard for patients with esophageal or gastroesophageal junction cancer who still had residual disease after neoadjuvant chemoradiotherapy and a microscopically complete R0 resection. In the original analysis, nivolumab extended disease-free survival to 22.4 months compared with 11.0 months for placebo, a hazard ratio of 0.69. The 2025 ASCO update confirmed that the benefit endures: disease-free survival remained superior at long-term follow-up (hazard ratio 0.76), distant metastasis-free survival improved as well (hazard ratio 0.75), and a favorable five-year overall survival trend emerged of 46 percent versus 41 percent. Toxicity stayed manageable, with grade 3 to 4 treatment-related adverse events in roughly 14 percent of patients and no new safety signals. Notably, the benefit was more pronounced in squamous cell carcinoma and in tumors with a PD-L1 combined positive score of at least 1, an early hint that biomarker selection will govern who truly benefits.

Alternative adjuvant strategies have fared less well, and the failures are as instructive as the successes. A randomized phase II trial of adjuvant durvalumab in esophageal squamous cell carcinoma showed no improvement in disease-free or overall survival overall, although exploratory analyses hinted at a striking benefit in PD-L1-positive tumors, where 36-month overall survival reached 94 percent versus 64 percent in the control arm. Meanwhile, the European VESTIGE trial tested intensified dual immunotherapy, nivolumab plus ipilimumab, against standard adjuvant chemotherapy in high-risk gastroesophageal junction adenocarcinoma, and the results were sobering: disease-free survival was actually inferior in the immunotherapy arm at 11.4 versus 20.8 months, forcing early termination of the study. Taken together, the review concludes that adjuvant nivolumab after neoadjuvant chemoradiotherapy remains the only strategy with consistent and durable benefit, and that in East Asia, where chemotherapy-based neoadjuvant regimens predominate for squamous disease, the postoperative immunotherapy question remains open pending confirmatory phase III evidence.

Before surgery, the picture is more heterogeneous and histology matters enormously. In adenocarcinoma, the evidence for adding checkpoint inhibitors to perioperative chemotherapy remains inconsistent. The phase III KEYNOTE-585 trial raised pathological complete response rates with perioperative pembrolizumab plus FLOT chemotherapy but failed to deliver a statistically significant event-free survival benefit, and the PERFECT trial of atezolizumab with the CROSS chemoradiation regimen achieved a 25 percent pathological complete response rate without improving survival over matched historical controls. Squamous cell carcinoma tells a different story. Early phase II studies of pembrolizumab-based neoadjuvant therapy reported pathological complete response rates around 45 to 55 percent, and next-generation PD-1 inhibitors have built on that foundation. The TD-NICE trial of tislelizumab plus chemotherapy achieved high pathological response rates without treatment-related deaths or surgical delays, while the RATIONALE-306 trial had already demonstrated an overall survival benefit for the drug in advanced disease.

The strongest phase III signal in the neoadjuvant setting comes from China. In the ESCORT-NEO/NCCES01 trial, 391 patients with resectable esophageal squamous cell carcinoma were randomized to chemotherapy with or without camrelizumab. The addition of the immunotherapy agent nearly doubled pathological complete response rates, reaching 28.0 percent with nanoparticle albumin-bound paclitaxel plus cisplatin and 15.4 percent with conventional paclitaxel plus cisplatin, compared with just 4.7 percent for chemotherapy alone. Crucially, this came without excess surgical morbidity, which ranged from 34 to 39 percent across arms. A network meta-analysis ranked camrelizumab plus chemotherapy highest for pathological responses, while pembrolizumab-based regimens showed the best objective response and disease control rates. Meta-analyses across histologies confirm that neoadjuvant immunochemotherapy and immunochemoradiotherapy achieve high response rates with surgical feasibility comparable to conventional regimens, and grade 3 or worse adverse event rates of roughly 20 to 35 percent, similar to established treatments.

For the operating room itself, timing and technique are being codified. Surgery across trials was typically scheduled four to six weeks after the last immunotherapy dose, an interval long enough to resolve immune-related inflammation but short enough to avoid progressive fibrosis. Common immune-related adverse events such as rash, thyroid dysfunction, and pneumonitis are usually low grade and manageable, but surgeons must watch for them, since operating through an unresolved pneumonitis or impaired wound healing would be hazardous. Real-world and multicenter analyses have shown that minimally invasive esophagectomy after neoadjuvant chemoimmunotherapy produces complication rates, operating times, pneumonia, and anastomotic leakage figures comparable to surgery alone. Perhaps most provocatively, a meta-analysis of 14 studies encompassing 3,212 patients found that complete lymph node regression and nodal downstaging after therapy were strongly associated with survival, with hazard ratios of roughly 0.47 for overall survival and 0.42 for disease-free survival, raising the prospect of tailoring the extent of lymphadenectomy to each patient’s pathological response.

The second pillar of the new paradigm is the aging patient. The benefit of neoadjuvant chemotherapy in the elderly depends far more on physiology than on birth certificates: a multicenter study showed that preoperative chemotherapy significantly improved five-year overall survival only among patients with a performance status of zero, from 38.1 to 56.5 percent, while those with any impairment of daily function saw no benefit. Real-world data indicate that dose reductions in later chemotherapy cycles are safe in patients over 70 without compromising long-term survival, and a 2025 nationwide Japanese database study found comparable perioperative morbidity between doublet and docetaxel-based triplet regimens in older patients, supporting selection by physiological reserve rather than chronological age. Body composition emerges as a decisive variable. Meta-analyses from 2024 and 2025 show that sarcopenia, the loss of skeletal muscle mass, nearly doubles the risk of poor overall and disease-free survival and increases postoperative complications by about 30 percent, with sarcopenic obesity carrying the worst prognosis of all.

Nutrition and conditioning complete the geriatric assessment. The Geriatric Nutritional Risk Index, categorized above 98, between 92 and 98, and below 92, has been repeatedly validated as a predictor of survival and postoperative morbidity, including in a 2024 pan-cancer analysis. Prehabilitation, structured exercise and nutrition programs delivered before surgery, reduced postoperative pneumonia by nearly 30 percent in a meta-analysis of upper gastrointestinal cancer studies and shortened hospital stays, and systematic reviews in esophagectomy specifically found pulmonary complication odds ratios around 0.35 to 0.48 in prehabilitation cohorts. For patients whose disease recurs after definitive chemoradiotherapy, salvage surgery, once feared for its mortality, has become a realistic curative option in selected cases. The multicenter SURGES study reported three-year overall survival of approximately 49 percent with 90-day mortality of just 3.3 percent, and minimally invasive salvage techniques cut overall complications and pneumonia roughly in half compared with open surgery. Even oligometastatic disease may benefit, with local therapy extending median survival from 7.8 to 35.2 months in one observational cohort.

The third pillar is technological. Artificial intelligence models trained on robotic surgical videos are learning to identify the recurrent laryngeal nerve, a structure whose injury causes vocal cord paralysis and whose preservation is among the most delicate steps of esophagectomy. One model trained on 120 robot-assisted procedures achieved respectable segmentation scores and, more strikingly, helped trainee surgeons recognize the nerve earlier in 81.3 percent of cases versus 46.9 percent for controls. A follow-up proof-of-concept study showed that AI could detect excessive traction on the nerve with 84.4 percent accuracy before changes appeared on conventional electromyographic monitoring, opening a window for corrective action before injury occurs. Beyond the operating theater, machine learning is reshaping planning: radiomics models predict lymph node metastasis with areas under the curve approaching 0.74 to 0.89, deep learning predicts pathological complete response after chemoimmunotherapy with AUCs of 0.83 to 0.92, and gradient boosting models outperform established risk scores for predicting 90-day mortality. Integration with circulating tumor DNA, whose postoperative positivity strongly signals recurrence risk, promises molecularly grounded risk stratification.

The review’s conclusion is a call for synthesis. Virtual reality simulators and AI-driven feedback systems are standardizing training in robotic esophagectomy, validated procedure-specific rehearsal tools and international consensus curricula are emerging, and automated frameworks can now evaluate suturing performance in real time. When the stomach cannot serve as the replacement conduit, free jejunal grafts with microvascular anastomosis offer a reliable alternative, and thoracoscopic esophagectomy has proven non-inferior to open surgery in the landmark JCOG1409 trial, with robotic and transmediastinal approaches broadening options for patients with poor pulmonary reserve. What unites these threads is a philosophy: the surgeon of the coming decade will not simply execute an operation but will select, time, and integrate surgery within a multidisciplinary pathway informed by tumor biology, ctDNA, radiomics, frailty indices, and machine intelligence. The future of esophageal cancer surgery, the authors argue, will be defined not by technical precision alone, but by the capacity to fuse biological insight, data intelligence, and clinical judgment into genuinely personalized care.

Subject of Research: Integrating immunotherapy, frailty assessment, and artificial intelligence into personalized surgical strategies for esophageal cancer

Article Title: Essential Updates 2024–2025: Surgical Strategy for Esophageal Cancer Toward a New Paradigm in the Era of Immunotherapy and Personalization

Article References: Oya, S., Yagi, K., & Baba, Y. (2026). Essential Updates 2024–2025: Surgical Strategy for Esophageal Cancer Toward a New Paradigm in the Era of Immunotherapy and Personalization. Annals of Gastroenterological Surgery, 10(5), 1368-1381. https://doi.org/10.1002/ags3.70197

Image Credits: AI Generated

DOI: 10.1002/ags3.70197

Keywords: esophageal cancer, immunotherapy, immune checkpoint inhibitors, esophagectomy, neoadjuvant therapy, nivolumab, sarcopenia, prehabilitation, artificial intelligence, robotic surgery, salvage surgery, personalized medicine